The adoptive transfer of CAR-T cells, which are modified T cells expressing chimeric antigen receptors (CARs), to target B cell maturation antigen (BCMA) has demonstrated impressive results in treating relapsed/refractory multiple myeloma. Although BCMA CAR-T therapy induces certain complications in some patients, idiopathic thrombocytopenic purpura (ITP) has not been reported as one of them. To the best of our knowledge, this is the first report of the successful treatment of ITP that arose in a relapsed/refractory multiple myeloma patient following anti-BCMA CAR-T cell infusion. Herein, we describe this relatively uncommon complication and provide guidance on its treatment.
Keywords: B cell maturation antigen; BCMA CAR-T therapy; BCMA, B cell maturation antigen; CAR-Ts, chimeric antigen receptor T cells; CARS, chimeric antigen receptors; CR, complete remission; CRS, cytokine release syndrome; Chimeric antigen receptor T cells; ITP, idiopathic thrombocytopenic purpura; Idiopathic thrombocytopenic purpura; Relapsed/refractory multiple myeloma.
© 2020 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.